Tag Archives: EXEL

The EVP, Scientific Strategy & CSO of Exelixis (NASDAQ: EXEL) is Buying Shares

Yesterday, the EVP, Scientific Strategy & CSO of Exelixis (EXEL – Research Report), Peter Lamb, bought shares of EXEL for $897.9K. Following this transaction Peter Lamb’s holding in the company was increased by 1767.22% to a total of $3.18 million.

Exelixis (EXEL) Receives a Buy from Oppenheimer

In a report released yesterday, Silvan Tuerkcan from Oppenheimer maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $28. The company’s shares closed yesterday at $20.55. Tuerkcan commented: “EXEL has come under pressure following

Exelixis (EXEL) Receives a Buy from Cowen & Co.

In a report issued on April 21, Yaron Werber from Cowen & Co. maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of $29. The company’s shares closed yesterday at $20.61. According to TipRanks.com, Werber

Oppenheimer Believes Exelixis (NASDAQ: EXEL) Still Has Room to Grow

Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Exelixis (EXEL – Research Report) today. The company’s shares opened today at $24.33, close to its 52-week high of $25.31. Tuerkcan has an average return of 7.5% when recommending Exelixis. According

Cowen & Co. Maintains a Buy Rating on Exelixis (EXEL)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of $29. The company’s shares opened today at $22.32. According to TipRanks.com, Werber is ranked #383 out of

Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), ADMA Biologics (ADMA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exelixis (EXEL – Research Report) and ADMA Biologics (ADMA – Research Report) with bullish sentiments. Exelixis (EXEL) Oppenheimer analyst Silvan Tuerkcan maintained